Monoclonal antibody · Antagonist of granulocyte-macrophage colony-stimulating factor receptor alpha (CSF2RA) · developed by MedImmune LLC
Phase 2/3Most advanced trial (none active)
1Registered trials
What is Mavrilimumab?
Mavrilimumab is a human IgG4 monoclonal antibody that binds the alpha chain of the granulocyte-macrophage colony-stimulating factor receptor (GM-CSF-Rα), inhibiting GM-CSF-mediated signaling in granulocytes and monocytes. It is being studied in COVID-19 and pneumonia.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.